Provided by Tiger Trade Technology Pte. Ltd.

Kymera Therapeutics, Inc.

119.80
-1.7000-1.40%
Volume:503.43K
Turnover:61.16M
Market Cap:9.96B
PE:-37.30
High:125.71
Open:122.87
Low:119.77
Close:121.50
52wk High:130.05
52wk Low:39.84
Shares:83.15M
Float Shares:70.11M
Volume Ratio:0.78
T/O Rate:0.72%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2122
EPS(LYR):-3.6900
ROE:-24.15%
ROA:-15.59%
PB:6.60
PE(LYR):-32.47

Loading ...

A Look At Kymera Therapeutics (KYMR) Valuation After Late Breaking KT-621 AAD 2026 Selection

Simply Wall St.
·
Mar 22

Kymera Therapeutics director Pamela Esposito disposes of USD 198,920 in common shares

Reuters
·
Mar 21

Kymera Therapeutics Coverage Assumed by Jefferies at Buy

Dow Jones
·
Mar 17

U.S. RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Cogent Biosciences, Summit Therapeutics

Reuters
·
Mar 16

Kymera Therapeutics COO Jeremy G Chadwick Disposes of Common Shares

Reuters
·
Mar 12

Kymera Therapeutics to present KT-621 Phase 1b data at AAD 2026 annual meeting

Reuters
·
Mar 10

Kymera Therapeutics Director Bruce Booth Disposes of Common Shares

Reuters
·
Mar 05

Kymera Therapeutics Is Maintained at Buy by UBS

Dow Jones
·
Mar 04

UBS Adjusts Price Target on Kymera Therapeutics to $128 From $90, Maintains Buy Rating

MT Newswires Live
·
Mar 03

How Kymera’s Bigger Losses and New Equity Plans May Impact Kymera Therapeutics (KYMR) Investors

Simply Wall St.
·
Mar 03

Kymera Therapeutics Is Maintained at Overweight by Stephens & Co.

Dow Jones
·
Mar 02

Wells Fargo Remains a Buy on Kymera Therapeutics (KYMR)

TIPRANKS
·
Mar 02

Analysts Are Bullish on Top Healthcare Stocks: Arcutis Biotherapeutics (ARQT), Kymera Therapeutics (KYMR)

TIPRANKS
·
Mar 02

Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (WVE) and Kymera Therapeutics (KYMR)

TIPRANKS
·
Feb 28

Kymera Therapeutics Signals Strong Momentum In Earnings Call

TIPRANKS
·
Feb 28

Kymera Therapeutics: Advancing Differentiated Oral Immunology Assets with Multi-Indication Runway Through 2029

TIPRANKS
·
Feb 27

Assessing Kymera Therapeutics (KYMR) Valuation After Equity Offering Losses And Leadership Change

Simply Wall St.
·
Feb 27

Stock Track | Kymera Therapeutics Soars 5.04% Intraday as Analysts Maintain Bullish Ratings Despite Q4 Miss

Stock Track
·
Feb 27

Kymera Therapeutics price target lowered to $123 from $127 at Morgan Stanley

TIPRANKS
·
Feb 27

Kymera Therapeutics Is Maintained at Buy by BTIG

Dow Jones
·
Feb 27